Health Affairs May 8, 2018
There has never been a good time to be diagnosed with cancer, but the past few years have seen major progress made in some of the most recalcitrant types of tumors. Two major developments are responsible:
- The mainstreaming of immunotherapy, which was until circa 2009 a niche treatment used by a very select number of large academic centers, and
- The increasing understanding of the driving genomic mutations in cancer, along with the advancing ability to synthesize “targeted” agents to leverage vulnerabilities introduced by these mutations.
Unleashing the immune system through the use of drugs such as checkpoint inhibitors and introducing entirely new immune systems through human and synthetic means (through stem cell transplants and CAR T-cells, respectively) has...
Today's Sponsors
Today's Sponsor